Annovis Bio Reports Significant Progress in Phase 3 Alzheimer's Trial and Corporate Milestones

Annovis Bio Inc. (NYSE: ANVS) has reported substantial third quarter 2025 progress marked by the complete activation of all 84 clinical sites in its pivotal Phase 3 Alzheimer's study (NCT06709014) alongside steady patient enrollment across the United States. The late-stage clinical drug platform company, which focuses on developing therapies for neurodegenerative diseases including Alzheimer's and Parkinson's, also revealed encouraging biomarker data from its Phase 2/3 Alzheimer's trial demonstrating significant reductions in inflammation and neurodegeneration. These findings provide strong evidence supporting buntanetap's disease-modifying potential in treating Alzheimer's disease, a condition affecting millions worldwide with limited effective treatment options currently available.

The company's recent achievements extend beyond clinical progress to include important corporate milestones that strengthen its overall position. Annovis successfully transferred all patents related to the new crystal form of buntanetap, securing intellectual property protection through 2046. This extended IP protection provides long-term exclusivity for the company's lead compound, potentially enhancing its commercial value and investment appeal. Additionally, the company has published supportive pharmacokinetic data that further validates buntanetap's profile and appointed veteran finance executive Mark Guerin as Chief Financial Officer, bolstering the company's financial leadership during this critical development phase.

Maria Maccecchini, Ph.D., president and CEO of Annovis Bio, emphasized the significance of these developments, stating that every element is now aligned as the company moves toward its data readouts. These upcoming readouts represent the final step before submitting a New Drug Application (NDA) to regulatory authorities. The full activation of clinical sites and steady enrollment progress suggest the Phase 3 trial is advancing according to schedule, potentially bringing the company closer to delivering a much-needed treatment option for Alzheimer's patients. For additional information about the company's developments, visit https://www.annovisbio.com.

The convergence of clinical progress and corporate strengthening comes at a crucial time for Alzheimer's research, with the field actively seeking effective disease-modifying treatments. The biomarker data showing reductions in inflammation and neurodegeneration is particularly significant as these pathological processes are central to Alzheimer's disease progression. If buntanetap continues to demonstrate efficacy in reducing these key disease markers while maintaining safety, it could represent a meaningful advancement in Alzheimer's therapeutics. The company's comprehensive approach addressing both clinical development and corporate infrastructure positions Annovis Bio as it progresses toward potentially transformative data readouts that could shape the future of Alzheimer's treatment.